NanoViricides Inc Dossier - Source-backed chat

NanoViricides Inc

NNVCNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.45

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.26Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $32.2M

Enterprise Value $28.9M

Shares Outstanding 25.5M diluted

Next Earnings Date14 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

NanoViricides, Inc. (NNVC) is a clinical-stage biopharmaceutical company utilizing its proprietary TheraCour® nanomedicine platform to develop broad-spectrum antiviral therapies. Its lead candidate, NV-387, has demonstrated excellent safety in Phase I trials and is poised to enter Phase II trials for Mpox and Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC). While the platform's 'Re-Infection Inhibition' decoy mechanism offers a highly differentiated, escape-resistant approach to viral treatment, the company remains pre-revenue with a substantial accumulated deficit of $154.8 million. Despite a recent $2.0 million registered direct offering, its cash runway of $3.38 million (as of March 31, 2026) is insufficient to support all planned global clinical objectives through mid-2027. Consequently, a Hold recommendation is advised, balancing the high-reward potential of its broad-spectrum platform against near-term clinical execution and dilution risks.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$6.00

High · most bullish analyst$6.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case involves prolonged operational delays in setting up clinical trial sites in the DRC, leading to slow patient enrollment for Mpox and Ebola. With a limited cash runway, the company is forced to execute highly dilutive equity financings at depressed share prices. Failure to secure non-dilutive government funding or partnerships, combined with potential safety or efficacy setbacks in the field, would severely impair the valuation of the TheraCour® platform.

Base CaseCentral scenario

The base case assumes NanoViricides successfully initiates and completes its Phase II Mpox trial in the DRC, demonstrating safety and preliminary efficacy. This clinical progress, combined with its FDA Orphan Drug Designation for Measles, could attract non-dilutive biodefense funding (e.g., from BARDA) or a strategic partnership with a larger pharmaceutical firm to co-develop NV-387 for respiratory indications like RSV and Influenza. However, ongoing cash burn will necessitate further dilutive capital raises under its newly filed $50 million shelf registration, capping near-term equity upside.

Bull CaseUpside scenario

NanoViricides' proprietary TheraCour nanomedicine platform enables the development of broad-spectrum, host-mimetic antivirals like NV-387 that target host-cell attachment mechanisms, making viral escape via mutation highly unlikely. The lead candidate NV-387 is being advanced into Phase II clinical trials for Mpox and Bundibugyo Ebolavirus in the DRC, utilizing a highly stable, patient-friendly oral gummy formulation that simplifies distribution in low-resource settings. Additionally, the company's fully owned, unmortgaged multi-kilogram-scale cGMP manufacturing facility in Shelton, CT, provides significant cost savings and rapid clinical supply capabilities.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary TheraCour® platform technology provides a unique 'host-mimetic' decoy mechanism that prevents viral escape and enables broad-spectrum activity against multiple viral families (RSV, Influenza, Coronaviruses, Poxviruses, Filoviruses).
Lead candidate NV-387 has successfully completed a Phase I clinical trial in healthy volunteers with zero dropouts and no reported adverse events, establishing a strong safety profile.
In-house cGMP-compliant manufacturing facility in Shelton, CT, provides tight control over proprietary chemical processes and rapid clinical-scale production, avoiding third-party CMO bottlenecks.
Orphan Drug Designation granted by the US FDA for NV-387 in Measles provides 7 years of market exclusivity, tax credits, and fee waivers, with pending applications for Mpox and Smallpox.

Key Investment Risks

Pre-revenue clinical-stage company with a history of operating losses and an accumulated deficit of $154.8 million as of March 31, 2026.
Limited cash runway of $3.38 million as of March 31, 2026, which is insufficient to fund all planned clinical programs through May 2027, creating high near-term dilution risk.
Geopolitical and operational risks associated with conducting primary Phase II clinical trials in the Democratic Republic of Congo (DRC).
High dependence on TheraCour Pharma, Inc. (a related party owned by the CEO) for intellectual property licensing and ongoing chemical development.

Thesis Invalidation Triggers

Failure to initiate patient dosing in the Phase II Mpox trial in the DRC by the end of 2026.
Any serious adverse events (SAEs) reported during the Phase II clinical trials of NV-387.
Inability to secure additional capital or non-dilutive funding before the current cash runway is exhausted, leading to a suspension of clinical programs.
Rejection of the Rare Pediatric Disease Designation (RPDD) application for NV-387 in Measles by the US FDA.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.